These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22695620)

  • 41. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues.
    Manfredsson FP; Bloom DC; Mandel RJ
    Neurobiol Dis; 2012 Nov; 48(2):212-21. PubMed ID: 22426391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carrier-mediated delivery of metabotrophic glutamate receptor ligands to the central nervous system: structural tolerance and potential of the L-system amino acid transporter at the blood-brain barrier.
    Reichel A; Begley DJ; Abbott NJ
    J Cereb Blood Flow Metab; 2000 Jan; 20(1):168-74. PubMed ID: 10616805
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles.
    Liu Y; Huang R; Han L; Ke W; Shao K; Ye L; Lou J; Jiang C
    Biomaterials; 2009 Sep; 30(25):4195-202. PubMed ID: 19467700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exosomes and the blood-brain barrier: implications for neurological diseases.
    Wood MJ; O'Loughlin AJ; Samira L
    Ther Deliv; 2011 Sep; 2(9):1095-9. PubMed ID: 22833906
    [No Abstract]   [Full Text] [Related]  

  • 46. Diazenyl derivatives as therapeutic and diagnostic agents acting on central nervous system.
    Kaur H; Yadav S; Narasimhan B
    Cent Nerv Syst Agents Med Chem; 2015; 15(1):42-51. PubMed ID: 25675399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Gene therapy in neurological diseases].
    Głabiński AR
    Neurol Neurochir Pol; 2001; 35(6):1111-9. PubMed ID: 11987706
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Applied neurogenomics.
    Jain KK
    Pharmacogenomics; 2001 May; 2(2):143-52. PubMed ID: 11368753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brain transporters: From genes and genetic disorders to function and drug discovery.
    Vandenberg RJ; Ryan R; Broer S
    Neurochem Int; 2016 Sep; 98():1-3. PubMed ID: 27475459
    [No Abstract]   [Full Text] [Related]  

  • 50. Channelrhodopsins-Their potential in gene therapy for neurological disorders.
    Ji ZG; Ishizuka T; Yawo H
    Neurosci Res; 2013 Jan; 75(1):6-12. PubMed ID: 23026479
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estrogen actions in the nervous system: Complexity and clinical implications.
    Cersosimo MG; Benarroch EE
    Neurology; 2015 Jul; 85(3):263-73. PubMed ID: 26109716
    [No Abstract]   [Full Text] [Related]  

  • 52. Neurological gene therapy.
    Fooks AR; Jennings AD; Doyle A; Clegg JC; Stacey GN
    Sci Prog; 1997; 80 ( Pt 2)():107-24. PubMed ID: 9263509
    [No Abstract]   [Full Text] [Related]  

  • 53. Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017.
    Greenwood J; Hammarlund-Udenaes M; Jones HC; Stitt AW; Vandenbroucke RE; Romero IA; Campbell M; Fricker G; Brodin B; Manninga H; Gaillard PJ; Schwaninger M; Webster C; Wicher KB; Khrestchatisky M
    Fluids Barriers CNS; 2017 Nov; 14(1):31. PubMed ID: 29110676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene therapy for childhood neurological disease.
    Sahin M
    Pediatr Neurol; 2014 Nov; 51(5):595-6. PubMed ID: 25439574
    [No Abstract]   [Full Text] [Related]  

  • 55. The blood-brain barrier and neurotherapeutics.
    Pardridge WM
    NeuroRx; 2005 Jan; 2(1):1-2. PubMed ID: 15717052
    [No Abstract]   [Full Text] [Related]  

  • 56. Current Trends for Rationalizing Brain Targeting Nanoparticles in Neurological Disorders (Part-I).
    Javed MN; Ashraf GM; Barreto GE; Naim MJ
    Curr Drug Metab; 2020; 21(9):648. PubMed ID: 33327901
    [No Abstract]   [Full Text] [Related]  

  • 57. [Gene therapy of nervous system diseases in children].
    Gressens P
    Arch Pediatr; 1996 Nov; 3(11):1136-8. PubMed ID: 8952780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Perspectives in gene therapy for MS.
    Martino G
    Int MS J; 2003 Aug; 10(3):84-8. PubMed ID: 14561374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trends in Rationalized Brain Targeted Nanoparticles in Neurological Disorders (Part-III).
    Javed MN; Ashraf GM; Barreto GE; Naim MJ
    Curr Drug Metab; 2021; 22(4):250. PubMed ID: 34170805
    [No Abstract]   [Full Text] [Related]  

  • 60. Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders.
    Muheem A; Jahangir MA; Jaiswal CP; Jafar M; Ahmad MZ; Ahmad J; Warsi MH
    Curr Drug Metab; 2021; 22(4):263-279. PubMed ID: 33305703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.